A number of pharmacological and pro-inflammatory stimuli have been shown to trigger phosphoinositide hydrolysis in macrophages (2). Similar to other cell types, GroPIns production in these cells is regulated by a Ca²⁺-dependent pathway involving the PLA₂-catalyzed deacylation of PtdIns (2). Studies on macrophages treated with cholera or pertussis toxin provided evidence that PLA₂ is activated downstream of G proteins, catalyzing the hydrolysis of PtdIns and leading to the production of arachidonic acid derivatives and GroPIns (12). A similar pathway was identified in Kupffer cells, the resident macrophages of the liver, following stimulation with inflammatory mediators produced upon bacterial endotoxin challenge (13, 14). A concerted activation of the arachidonate pathway and production of GroPIns has been reported in several other cell types (2).

PLA₂IVα, which had been identified as the specific, Ca²⁺-dependent PLA₂ responsible for GroPIns production in thyroid cells (4), has been recently demonstrated to carry out this function also in macrophages. Zizza and colleagues (5) showed that PLA₂IVα, which is abundantly expressed in macrophages, is phosphorylated by the MAP kinases Erk1/2 and by the stress-activated kinases p38 and JNK and translocates to the membrane of nascent phagosomes during Fc-Receptor (FcR)-mediated phagocytosis. A selective PLA₂IVα activation was observed to also occur upon LPS treatment which, similar to FcR engagement, triggers arachidonic acid release (5). Moreover, pharmacological inhibition of PLA₂IVα completely abolished both LPS- and phagocytosis-mediated GroPIns production. Interestingly, a time course analysis of GroPIns production during FcR-mediated phagocytosis revealed a persistent increase in the levels of intracellular GroPIns over time, which was paralleled by GroPIns release into the extracellular medium (our unpublished observations). This suggests that GroPIns may participate in the inflammatory responses of macrophages by acting not only in an autocrine manner, but also as a paracrine factor.

The intracellular levels of the GPIs have also been measured in T-cells. Mass spectrometry data showed that Jurkat T-cells are among the cell lines with low intracellular levels of GroPIns (45 ± 1 μM) (15, 16). Moreover, these basal levels are not increased by known pharmacological activators of PLA₂IVα, such as Ca²⁺ ionophores, or by chemotactic stimuli, such as CXCL12, which suggests that a Ca²⁺-independent enzyme is involved in GroPIns production in these cells. Alternatively, the concentrations of arachidonoyl-substituted PtdIns, the GPI precursor, may not be sufficient to produce significant increases in the levels of intracellular GroPIns.

Phospholipase A₂ activation is not only triggered by plasma-membrane receptors but also occurs during cell differentiation (17–19). Mountford and colleagues provided evidence that the levels of phosphoinositides change during the differentiation of both myeloid and lymphoid cells (20–22). Using HL60 promyelocytic cells, which can differentiate either to neutrophils in response to all-trans retinoic acid and granulocyte-colony-stimulating factor or to monocytes in response to 1α-25-dihydroxyvitamin D₃, they showed that the intracellular GroPIns levels increased in the early stages of differentiation to either lineages, eventually doubling in fully differentiated cells. Consistent with these findings, GroPIns levels increased in neutrophils that spontaneously differentiated in culture, as compared to the initial blasts (22). Similar experiments, carried out on paired cell lines representative of immature and mature states of B-lymphocytes (Ba/F3 and NSI cells) and T-lymphocytes (S49 and C8166 cells) showed substantial increases in GroPIns levels in the cells representative of the mature states (22). Although more accurate methods to quantitate GroPIns as well as more physiological differentiation conditions will be required to validate these data, the changes in the concentrations of intracellular GroPIns suggest a role for this metabolite in the regulation of both myeloid and lymphoid cell differentiation.

In addition to GroPIns, its monophosphorylated derivative, GroPIns4P, has been detected in several cell types, including macrophages [(2); our unpublished observations)]. PLA₂IVα, is responsible for the production of both GPIs (i.e., GroPIns and GroPIns4P), based on the relative availability of the respective lipid precursors (PtdIns and PtdIns4P, respectively) [(4, 5); our unpublished observations]. A conundrum in these studies are the technical limitations in the accurate measurement of these metabolites. For example, the relatively high levels of GroPIns make the detection of small increases more difficult, which might explain why increases in GroPIns4P (which generally represents<3% of the total GPIs) do not always appear to be paralleled by increases in GroPIns. The rapid metabolism of GroPIns4P is a further drawback for precise determinations of its levels, although this was partially overcome by performing GroPIns4P measurements in the presence of orthovanadate, a general phosphatase inhibitor (2), which made it possible to monitor GroPIns4P increases in macrophages exposed to LPS (our unpublished observation). At variance with macrophages, no detectable production of GroPIns4P can be observed in T-cells (16).

Cortical actin rearrangements, which are regulated by the Rho family of small GTPases (23), are crucial for a number of processes that orchestrate T-lymphocyte activation and motility (24, 25). Exogenous administration of GroPIns4P to fibroblasts induces the formation of actin ruffles and stress fibers by modulating the activity of Rac and Rho (26, 27), suggesting a potential role for this phosphoinositide derivative in the regulation of the actin cytoskeleton in other cell types. Treatment of both Jurkat T-cells and peripheral blood lymphocytes from healthy donors with GroPIns4P induces indeed actin polymerization (16), suggesting that the processes involving F-actin dynamics, including redistribution of components associated with lymphocyte motility and immune synapse assembly might be modulated by GroPIns4P.

The ability of GroPIns4P to promote actin polymerization in T-cells stems, at least in part, from its ability to induce the phosphorylation of the GDP/GTP exchanger Vav (16), which controls the activation of Rac and Cdc42 in hematopoietic cells (28). These data are consistent with the finding that GroPIns4P triggers a signaling cascade in fibroblasts that leads to plasma-membrane translocation of Tiam1, a Rac-specific GDP/GTP exchanger in these cells (27). This activity provides a mechanistic explanation of the agonistic effects of GroPIns4P on the actin cytoskeleton dynamics.

The ability of GroPIns4P to promote Vav activation suggests the possibility that it may also modulate gene expression. Vav initiates indeed a pathway involving recruitment to active Rac of the serine/threonine kinase Pak1, which triggers the activation of p38 and JNK that directly or indirectly activate a number of transcription factors (29). Consistent with this notion, T-cell treatment with GroPIns4P resulted in activation of both p38 and JNK, with a similar time course as Vav (16).

Tyrosine phosphorylation of Vav is mediated by the cooperative activity of Syk and Src family protein tyrosine kinases (PTKs) (28). We have shown that treatment of T-cells with GroPIns4P results in enhanced Lck activity [(16); Figure 2]. Although other mechanisms may account for Vav activation, this event is likely to be causal to the agonistic activity of GroPIns4P on Vav activation and the resulting actin cytoskeleton rearrangements. GroPIns4P fails indeed to trigger Vav phosphorylation in the Lck-deficient Jurkat T-cell variant JCaM.1 (16, 30). Moreover, GroPIns4P triggers Src phosphorylation in fibroblasts, which is required for plasma-membrane translocation of Tiam1 (27). Lck activation, as well as Src activation, is not a direct effect of GroPIns4P, at least as assessed in vitro (16). Unfortunately, while these studies have restricted the field, no final mechanism of action for the GPIs can be postulated, until a proteomic approach to identify direct interactors can be completed.

In quiescent T-cells Lck is kept in an inactive state by the inhibitory kinase Csk, which becomes phosphorylated and activated by the cAMP-dependent serine/threonine protein kinase A (PKA) (31). We showed that treatment of Jurkat T-cells with GroPIns4P results in a decrease in the levels of cAMP, leading to impaired PKA activation and Csk phosphorylation. Hence the agonistic activity of GroPIns4P on Lck activation and downstream signaling results from its ability to inhibit cAMP production (16). These results are consistent with the finding that GroPIns4P (but not GroPIns or GroPIns4,5P₂) inhibits adenylate cyclase activity in other cell types (32, 33). It is noteworthy that cAMP/PKA-mediated modulation of molecules downstream of Lck may also contribute to its effects on F-actin dynamics in T-cells (34), including Rho itself, which is phosphorylated by PKA on an inhibitory residue (35, 36).

The ability of GroPIns4P to activate Lck, which is responsible for initiation of the T-cell receptor (TCR) signaling cascade, strongly suggests that other signaling events, in addition to the Vav/p38/JNK pathway, might be triggered by GroPIns4P. One of the key targets of Lck both in TCR (37) and chemokine receptor signaling (38) is the PTK ZAP-70, which couples these receptors to multiple signaling pathways, including the Ras/MAP kinase pathway (39). GroPIns4P induces indeed the activation of ZAP-70 and the adaptor Shc (16), which interacts with, and becomes phosphorylated by ZAP-70 in response to TCR engagement and contributes to Ras activation by recruiting the Grb2/Sos complex (40). Consistent with its ability to promote Shc phosphorylation, GroPIns4P activates Erk1/2. These effects of GroPIns4P are crucially dependent on Lck, as they fail to occur in JCaM.1 cells (16).

The ability of GroPIns4P to promote actin polymerization in T-cells profoundly influences their responses to chemokines. GroPIns4P (but not the other GPIs) enhances indeed CXCR4-dependent chemotaxis toward CXCL12 (16), a chemokine that regulates lymphocyte homing to secondary lymphoid organs under homeostatic conditions (39). Interestingly, the two signals may converge, at least in part, on adenylate cyclase. In fact, CXCL12-mediated activation of CXCR4 promotes the release of the α-subunit of heterotrimeric inhibitory G protein (G_i), thereby inhibiting adenylate cyclase activity (39). Moreover, in Jurkat T-cells GroPIns4P reverses the cAMP-elevating activity of cholera toxin, which ADP-ribosylates the α-subunit of stimulatory G proteins (G_s) resulting in their persistent activation. This indicates that GroPIns4P is able to decrease cAMP production and cAMP/PKA-dependent Csk activation by inhibiting G_s. These mechanisms can account for the additive effect of CXCL12 and GroPIns4P on Lck activation [(16); Figure 2].

Recent evidence supports a crosstalk between the TCR and CXCR4. The TCR is indeed transactivated by CXCR4 which then uses the TCR machinery to elicit and potentiate downstream signaling (38, 41). Similar to other G-protein-coupled receptors, CXCR4 directly interacts with and activates Lck. The association of CXCR4 with the TCR at the cell surface allows Lck to localize in close contact with the intracellular domains of the TCR/CD3 complex and phosphorylate CD3ζ, thereby triggering downstream signaling (39). By promoting Lck activation GroPIns4P might potentiate the ability of CXCR4 to transactivate the TCR and hence enhance the signaling cascades leading to T-cell chemotaxis, including the pathway leading to the Lck-dependent recruitment of Shc to the CXCR4/TCR dimer.

How can the evidence obtained using exogenously added GroPIns4P be related to the physiological context of T-cell trafficking? Measurements of the GPI levels in Jurkat T-cells using a quantitative mass spectrometry approach revealed that these cells are among those with the lowest intracellular levels of GroPIns (15). At variance with T-cells, macrophages produce large amounts of GPIs in response to pro-inflammatory stimuli (2, 5), generating a gradient for their transporter-mediated release into the extracellular medium (2, 15, 42). We propose that these macrophage-derived GPIs may act as paracrine factors for lymphocytes. In this scenario, GPIs produced at the site of infection would enhance effector T-cell recruitment, and thereby contribute to bacterial clearance. Interestingly, among the highest GPI producers are certain tumor cells (2, 43). The release of these metabolites, combined with chemotactic signals provided by the tumor microenvironment (44), could be hypothesized to promote T-cell infiltration and activation of anti-tumor immunity.

By promoting the activation of Lck, exogenous administration of GroPIns4P to T-lymphocytes triggers a Rho-family dependent pathway that is integrated with chemokine receptor signaling to potentiate T-cell chemotaxis (16). Given the central role of Lck as the initiator kinase in TCR signaling (37), it can be hypothesized that GroPIns4P has the ability to modulate T-cell activation. Lck has also been implicated in the regulation of T-cell apoptosis induced by a wide range of stimuli, including prolonged TCR stimulation (45) and treatment with sphingosine (46), and it is also an essential component of the signaling pathways that control Ca²⁺-mediated T-cell apoptosis, which involve both the conformational activation of Bax and the expression of proapoptotic Bcl-2 family members (47). How TCR engagement can lead to cell fates as diverse as activation, anergy, and apoptosis is one of the fundamental and as yet open questions in immunology. Investigating the effects of GroPIns4P, as well as of the other GPIs, on these processes, may provide valuable information on how TCR signaling is fine-tuned by these phosphoinositide metabolites to elicit different biological outcomes.